PD-L1 cDNA Clone: Expression and Clone Vector / Plasmid

PD-L1 cDNA / Gene Overview

CD274 gene / cDNA is a protein-coding gene which located on 9p24.1. The CD274 gene is conserved in chimpanzee, Rhesus monkey, dog, cow, mouse, rat, chicken, zebrafish, and frog.160 organisms have orthologs with human gene CD274.

PD-L1 cDNA / Gene Function

This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]

PD-L1 cDNA / Gene Sequence

LOCUS
LOCUS NM_014143 3691 bp mRNA linear PRI 12-AUG-2018
DEFINITION
Homo sapiens CD274 molecule (CD274), transcript variant 1, mRNA.
ACCESSION
NM_014143
VERSION
NM_014143.3

This sequence information is just for reference only.

PD-L1 Family & Reagents

PD-L1 Gene family reagents (CD molecules)

Approved Symbol Reagent list
CD164
PTGFRN
FCRL2
CD160
CD33
PSG1
CD99
MME
TNFSF14
KIR2DL4
Approved Symbol Reagent list
CD180
PROCR
CD55
FASLG
LILRB4
IGSF8
TNFSF4
CSF1R
ICOSLG
FGFR2

PD-L1 Gene family reagents (Endogenous ligands)

Approved Symbol Reagent list
CCL14
FGF4
XCL1
INHBA
CXCL1
CSF3
VTN
VIP
PDCD1LG2
Fgf8
Approved Symbol Reagent list
CCL16
CCL13
CX3CL1
RAC1
GHRH
IL1RN
BMP2
INHBB
Spp1
CXCL13

PD-L1 Gene family reagents (V-set domain containing)

Approved Symbol Reagent list
CD300LG
MPZL3
FCAMR
GPA33
F11R
CADM4
NECTIN1
CEACAM3
AXL
NCR2
Approved Symbol Reagent list
CD4
CD300LF
SLAMF7
PSG6
SLAMF6
TIGIT
HEPACAM
HAPLN1
HHLA2
CRTAM

PD-L1 Gene family reagents (C2-set domain containing)

Approved Symbol Reagent list
KIRREL2
KIRREL1
ALCAM
NECTIN4
CRTAM
CADM2
PVR
BCAM
CADM1
CADM3
Approved Symbol Reagent list
MAG
CD2
AGER
CD200R1L
TMEM25
CD200R1
KIRREL3
CADM4
CD80
NECTIN3

PD-L1 cDNA / Gene Alias

  • B7 homolog 1
  • B7-H
  • B7H1
  • B7-H1
  • PDL1
  • PD-L1

PD-L1 cDNA / Gene Expression

Broad expression in appendix (RPKM 6.7), placenta (RPKM 4.5) and 23 other tissues

Recombinant PD-L1 protein citations

Title
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies
Year
2013
Author
BJ Chen, B Chapuy, J Ouyang, HH Sun…
Journal
Clinical Cancer research
Title
Society for Pediatric Pathology Fall Meeting, Salt Lake City, Utah, September 26–29, 2013
Year
2013
Author
C Galambos, S Sims-Lucas, AH Abman
Journal
Society for Pediatric Pathology Fall Meeting, Salt Lake City, UT
Title
PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
Year
2014
Author
Soliman, H;Khalil, F;Antonia, S;
Journal
PLoS ONE
Title
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis
Year
2015
Author
Massari, F;Ciccarese, C;Caliò, A;Munari, E;Cima, L;Porcaro, AB;Novella, G;Artibani, W;Sava, T;Eccher, A;Ghimenton, C;Bertoldo, F;Scarpa, A;Sperandio, N;Porta, C;Bronte, V;Chilosi, M;Bogina, G;Zamboni, G;Tortora, G;Samaratunga, H;Martignoni, G;Brunelli, M;
Journal
Target Oncol
Title
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
Year
2015
Author
Mahoney, KM;Sun, H;Liao, X;Hua, P;Callea, M;Greenfield, EA;Hodi, FS;Sharpe, AH;Signoretti, S;Rodig, SJ;Freeman, GJ;
Journal
Cancer Immunol Res
Title
Does smoking, age or gender affect the protein phenotype of extracellular vesicles in plasma?
Year
2016
Author
Bæk, R;Varming, K;Jørgensen, MM;
Journal
Transfus. Apher. Sci.
Title
Developing a LANCE TR-FRET Assay for Screening PD-1 and PD-L1 Binding Inhibitors
Year
2017
Author
Hinterneder, J;Hopkinton, MA;
Journal
Product
Title
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors
Year
2017
Author
Arbour, KC;Naidoo, J;Steele, KE;Ni, A;Moreira, AL;Rekhtman, N;Robbins, PB;Karakunnel, J;Rimner, A;Huang, J;Riely, GJ;Hellmann, MD;
Journal
PLoS ONE
Title
Gene signature driving invasive mucinous adenocarcinoma of the lung
Year
2017
Author
Guo, M;Tomoshige, K;Meister, M;Muley, T;Fukazawa, T;Tsuchiya, T;Karns, R;Warth, A;Fink-Baldauf, IM;Nagayasu, T;Naomoto, Y;Xu, Y;Mall, MA;Maeda, Y;
Journal
EMBO Mol Med
Title
Radiation therapy related down-regulation of PD-L1 on high-grade poorly differentiated sarcomas justify the combined radio-immunotherapy
Year
2017
Author
Wei, D;Canter, RJ;Qiu, H;Monjazeb, AM;
Journal
Abstract
Title
Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens
Year
2018
Author
Wedekind, MF;Haworth, KB;Arnold, M;Stanek, JR;Lee, D;Cripe, TP;
Journal
Pediatr Blood Cancer
Title
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
Year
2018
Author
Mo, H;Huang, J;Xu, J;Chen, X;Wu, D;Qu, D;Wang, X;Lan, B;Wang, X;Xu, J;Zhang, H;Chi, Y;Yang, Q;Xu, B;
Journal
Br. J. Cancer